Longevity

Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), is pleased to announce that the Company has entered into a memorandum of understanding with Celularity, for the commercial evaluation of Cynata’s Cymerus production technology for use with Celularity’s therapeutic stem cell technologies. As quoted in the press release: Celularity, Inc, is a leading US biotechnology …

Australian stem cell and regenerative medicine company, Cynata Therapeutics (ASX:CYP), is pleased to announce that the Company has entered into a memorandum of understanding with Celularity, for the commercial evaluation of Cynata’s Cymerus production technology for use with Celularity’s therapeutic stem cell technologies.
As quoted in the press release:

Celularity, Inc, is a leading US biotechnology company that uses its proprietary technology to harness cells from the postpartum placenta to address serious and life-threatening diseases, with strategic assets contributed from Celgene Corporation, Sorrento Therapeutics, United Therapeutics and Human Longevity, Inc.

Click here to read the full press release.

MARKETS

Markets
TSX18729.66-104.50
TSXV602.35-13.59
DOW31037.68+69.86
S&P 5003845.08+13.69
NASD11361.85+39.61
ASX6594.50-34.80

COMMODITIES

Commodities
Gold1747.09+6.69
Silver19.36+0.17
Copper3.49+0.08
Palladium1930.50+14.50
Platinum863.00+7.00
Oil98.86+0.33
Heating Oil3.46+0.05
Natural Gas5.56+0.05

DOWNLOAD FREE REPORTS

×